Motley Fool: A biotech bargain? - Sun, 11 Nov 2018 PST


Celgene has several years in which it still can profit handsomely from its multiple myeloma drug Revlimid, one of the best-selling drugs in the world. Celgene has several years in which it still can profit handsomely from its multiple myeloma drug Revlimid, one of the best-selling drugs in the world.



from Biotech News